Prestige Consumer Healthcare Inc. (NYSE:PBH) Holdings Decreased by Nuveen Asset Management LLC

Nuveen Asset Management LLC decreased its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 23.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 186,948 shares of the company’s stock after selling 58,673 shares during the quarter. Nuveen Asset Management LLC owned 0.38% of Prestige Consumer Healthcare worth $14,599,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of PBH. Kestra Investment Management LLC purchased a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at $27,000. CIBC Private Wealth Group LLC grew its holdings in shares of Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock valued at $34,000 after buying an additional 152 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at $40,000. Johnson Financial Group Inc. purchased a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at $93,000. Finally, Huntington National Bank grew its holdings in shares of Prestige Consumer Healthcare by 133.2% during the fourth quarter. Huntington National Bank now owns 1,481 shares of the company’s stock valued at $116,000 after buying an additional 846 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Insider Buying and Selling

In related news, SVP Mary Beth Fritz sold 1,678 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. The trade was a 8.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.60% of the stock is owned by insiders.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $85.98 on Monday. Prestige Consumer Healthcare Inc. has a fifty-two week low of $62.35 and a fifty-two week high of $90.04. The business has a 50-day moving average of $83.52 and a two-hundred day moving average of $82.30. The stock has a market capitalization of $4.25 billion, a P/E ratio of 20.14, a P/E/G ratio of 2.69 and a beta of 0.44. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The company had revenue of $296.52 million during the quarter, compared to analysts’ expectations of $289.36 million. During the same quarter in the previous year, the firm earned $1.02 earnings per share. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. On average, equities research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on PBH shares. Canaccord Genuity Group lifted their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a report on Friday, February 7th. Royal Bank of Canada upgraded Prestige Consumer Healthcare to a “hold” rating in a research note on Thursday, May 8th. Oppenheimer boosted their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a research note on Thursday, February 13th. Wall Street Zen upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, May 17th. Finally, DA Davidson boosted their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a research note on Friday, February 7th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.